Composition with hypoglycemic function and application thereof

Abstract

The invention provides a composition with a blood sugar reducing function and application thereof, and belongs to the technical field of diabetes treatment. The composition is prepared from burdock root extract, folium ilicis purpurea extract, hypoglycemic decapeptide, trehalose, sodium benzoate, glycerol, vitamin C and water. The composition disclosed by the invention has a multi-target synergistic effect, and by integrating natural plant extracts and functional peptides, multiple targets related to diabetes mellitus are adjusted, so that the blood sugar level is remarkably reduced, and cholesterol metabolism, oxidative damage and inflammatory response are effectively improved. The composition can be used for treating type 2 diabetes mellitus and has a good clinical application prospect.

Description

Technical Field

[0001] The present invention relates to the technical field of diabetes treatment, and in particular to a composition with blood sugar lowering function and application thereof. Background Art

[0002] Diabetes, a common chronic metabolic disease, is characterized by chronically elevated blood glucose levels, accompanied by metabolic abnormalities and oxidative damage. In recent years, the prevalence of diabetes has continued to rise, becoming a global public health issue. Chronic hyperglycemia can lead to a variety of complications, including cardiovascular disease, nephropathy, neuropathy, and retinopathy, severely impacting patients' quality of life and lifespan. Therefore, developing effective glucose-lowering treatments has become a research hotspot in the field of diabetes treatment.

[0003] Currently, hypoglycemic drugs primarily include insulin preparations and oral hypoglycemic agents (such as metformin, sulfonylureas, and DPP-4 inhibitors). While these drugs are effective in lowering blood sugar, they also carry numerous side effects. Natural extracts are currently attracting research attention due to their diversity and reduced side effects. Some plant extracts have been found to exhibit potential hypoglycemic mechanisms, including regulating insulin sensitivity, inhibiting the activity of glucose metabolism enzymes, and providing antioxidant benefits, offering new avenues for the development of hypoglycemic drugs. Against this backdrop, the present invention provides a novel hypoglycemic composition that integrates natural extracts with functional peptides to achieve multi-target hypoglycemic effects. Summary of the Invention

[0004] The purpose of the present invention is to provide a hypoglycemic composition that achieves a synergistic treatment of type 2 diabetes by achieving multi-target hypoglycemic effects.

[0005] In order to achieve the above-mentioned object, the present invention provides a composition with hypoglycemic function, which is composed of the following ingredients, calculated by mass percentage: 3%-5% burdock root extract, 1%-2% ivy extract, 0.1%-0.3% hypoglycemic decapeptide, 2%-3% trehalose, 0.2%-0.5% sodium benzoate, 0.5%-1% glycerol, 0.5%-0.75% vitamin C, and water supplemented to 100%; The amino acid sequence of the hypoglycemic decapeptide is LRSELAAWSR.

[0006] Preferably, the preparation method of the burdock root extract comprises the following steps: (1) Remove impurities from the dried burdock root, clean it, slice it, and grind it into burdock root powder; (2) Burdock root powder was mixed with 50% ethanol at a mass-to-volume ratio of 1:10 and ultrasonically extracted for 30 min at 50°C and 250W. (3) Filter using a filter to collect the extract a and the filter residue; (4) The filter residue was mixed with 70% ethanol at a mass-to-volume ratio of 1:10 and subjected to ultrasonic extraction for 30 min at a temperature of 50°C and a power of 250W; (5) Filtering with a filter to collect extract b, combining extract a and extract b to obtain a mixed extract; (6) Concentrating the mixed extract to 1 / 10 of the original volume to obtain a concentrated extract; (7) freeze-drying the concentrated extract to obtain a burdock root extract; The preparation method of the Sijiqing extract comprises the following steps: (1) Remove impurities from the dried Evergreen leaves, clean them, and grind them into Evergreen powder; (2) Add the Sijiqing powder to 50% ethanol solution at a mass-to-volume ratio of 1:10 and extract at room temperature for 24 hours; (3) Filter using a filter to collect the extract a and the filter residue; (4) The filter residue was mixed with 70% ethanol at a mass-to-volume ratio of 1:8 and extracted by ultrasonication at 40°C and 250W for 30 minutes; (5) Filtering with a filter to collect extract b, combining extract a and extract b to obtain a mixed extract; (6) Concentrate the mixed extract to 1 / 10 of its original volume using a rotary evaporator to obtain a concentrated extract; (7) The concentrated extract is freeze-dried to obtain the Sijiqing extract.

[0007] Preferably, the composition is composed of the following ingredients in percentage by mass: 3% burdock root extract, 2% ivy extract, 0.1% hypoglycemic decapeptide, 2% trehalose, 0.2% sodium benzoate, 1% glycerol, 0.75% vitamin C, and water supplemented to 100%.

[0008] Preferably, the composition is used to reduce elevated blood sugar caused by type 2 diabetes.

[0009] At the same time, the present invention provides a use of a composition in preparing a drug for treating type 2 diabetes. The composition is composed of the following ingredients, calculated by mass percentage: 3%-5% burdock root extract, 1%-2% ivy extract, 0.1%-0.3% hypoglycemic decapeptide, 2%-3% trehalose, 0.2%-0.5% sodium benzoate, 0.5%-1% glycerol, 0.5%-0.75% vitamin C, and water supplemented to 100%; The amino acid sequence of the hypoglycemic decapeptide is LRSELAAWSR; The burdock root extract is prepared according to the above-mentioned preparation method of burdock root extract; The Sijiqing extract is prepared according to the above-mentioned preparation method of the Sijiqing extract.

[0010] Preferably, the drug for treating type 2 diabetes is used to reduce elevated blood sugar caused by diabetes, and improve abnormal cholesterol metabolism, oxidative damage and inflammatory response caused by diabetes.

[0011] Preferably, the composition is composed of the following ingredients in percentage by mass: 3% burdock root extract, 2% ivy extract, 0.1% hypoglycemic decapeptide, 2% trehalose, 0.2% sodium benzoate, 1% glycerol, 0.75% vitamin C, and water supplemented to 100%.

[0012] In addition, the present invention provides a drug for treating type 2 diabetes, which is prepared by the following preparation method: (1) Add 2%-3% trehalose, 0.2%-0.5% sodium benzoate, and 0.5%-1% glycerol to water and stir evenly to obtain solution a; (2) Slowly add 3%-5% of burdock root extract and 1%-2% of evergreen holly extract, stirring continuously until completely dissolved, to obtain solution b; (3) Dissolve 0.1%-0.3% of the hypoglycemic decapeptide in water to obtain a hypoglycemic decapeptide solution, and slowly add it to solution b and stir evenly; (4) Add 0.5%-0.75% vitamin C, stir evenly, and add water to a total mass percentage of 100% to obtain solution C; (5) Solution c is sterilized by filtration using a 0.22 μm filter membrane to obtain a drug for treating type 2 diabetes.

[0013] Preferably, the amino acid sequence of the hypoglycemic decapeptide is LRSELAAWSR; The burdock root extract is prepared according to the above-mentioned preparation method of burdock root extract; The Sijiqing extract is prepared according to the above-mentioned preparation method of the Sijiqing extract.

[0014] Preferably, in terms of mass percentage, the added amount of trehalose is 2%, the added amount of sodium benzoate is 0.2%, the added amount of glycerol is 1%, the added amount of burdock root extract is 3%, the added amount of evergreen extract is 2%, the added amount of hypoglycemic decapeptide is 0.1%, and the added amount of vitamin C is 0.75%.

[0015] The beneficial effects of the present invention are: The hypoglycemic composition of this invention synergistically reduces blood glucose levels in treated mice by regulating multiple diabetes-related targets through burdock root extract, ivy extract, and hypoglycemic decapeptide. Simultaneously, through the multi-target synergistic effect of the three core components, it effectively improves cholesterol metabolism, oxidative damage, and inflammatory responses, thereby enhancing the overall therapeutic effect on patients with type 2 diabetes. Therefore, the hypoglycemic composition and therapeutic drug disclosed in this invention have significant clinical therapeutic potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is a graph showing the differences in fasting blood glucose concentrations among mice in different experimental groups; Figure 2 This is a graph showing the difference in serum total cholesterol levels among mice in different experimental groups; Figure 3 This is a graph showing the differences in serum SOD (superoxide dismutase) activity among mice in different experimental groups; Figure 4 This is a graph showing the differences in serum TNF-α (tumor necrosis factor-α) levels in mice in different experimental groups. DETAILED DESCRIPTION

[0017] The present invention will be further described below in conjunction with the accompanying drawings and specific implementation methods. It should be noted that, under the premise of no conflict, the various embodiments or technical features described below can be arbitrarily combined to form new embodiments.

[0018] Example 1: Preparation of burdock root extract Select dried burdock root, remove impurities, rinse with water, slice and grind into powder; The powder was mixed with 50% ethanol at a mass volume ratio of 1:10 (10 g:100 ml), and placed in a constant temperature ultrasonic extractor at 50°C, 250W, and extracted for 30 minutes; Filter through a 200-mesh filter to collect the extract a and the filter residue; The filter residue was mixed with 70% ethanol at a mass-to-volume ratio of 1:10 and placed in a constant temperature ultrasonic extractor at 50°C and 250W for 30 minutes. Filter through a 200-mesh filter to collect extract b, and combine extract a and extract b to obtain a mixed extract; The mixed extract was concentrated to 1 / 10 of the original volume using a rotary evaporator to obtain a concentrated extract; The concentrated extract is freeze-dried to obtain burdock root extract powder.

[0019] Example 2: Preparation of Sijiqing Extract in this Example Remove impurities from the dried Evergreen leaves, rinse with water, and grind into powder; The powder was added to 50% ethanol solution at a mass-to-volume ratio of 1:10 and extracted at room temperature for 24 hours; Filter through a 200-mesh filter to collect the extract a and the filter residue; The filter residue was mixed with 70% ethanol at a mass-to-volume ratio of 1:8 and placed in a constant temperature ultrasonic extractor at 40°C and 250W for 30 minutes. Filter through a 200-mesh filter to collect extract b, and combine extract a and extract b to obtain a mixed extract; The mixed extract was concentrated to 1 / 10 of the original volume using a rotary evaporator to obtain a concentrated extract; The concentrated extract is freeze-dried to obtain Sijiqing extract powder.

[0020] Example 3: This example prepares a composition and medicine with hypoglycemic function The composition comprises 3% burdock root extract, 2% ivy extract, 0.1% hypoglycemic decapeptide (amino acid sequence: LRSELAAWSR, synthesized by Nanjing GenScript Co., Ltd.), 2% trehalose, 0.2% sodium benzoate, 1% glycerol, 0.75% vitamin C, and water is added to make up the total amount 100%.

[0021] The steps of preparing the hypoglycemic drug of the present composition are as follows: (1) Prepare basic solution In a clean mixing container, add 60% water and keep stirring; Add trehalose (2%) and stir to dissolve until completely transparent; Add sodium benzoate (0.2%) and continue stirring; Add glycerol (1%) and stir until homogeneous; (2) Add plant extracts Slowly add burdock root extract (3%) to the stirring base solution, keeping stirring to ensure complete dissolution.

[0022] Then add the Evergreen Extract (2%) and keep stirring to ensure complete dissolution.

[0023] (3) Adding hypoglycemic decapeptides Dissolve the hypoglycemic decapeptide powder (0.2%) in 5% water and mix thoroughly to form a uniform hypoglycemic decapeptide solution.

[0024] Slowly add the hypoglycemic decapeptide solution to the stirring vessel and keep stirring to ensure uniform distribution.

[0025] (4) Add antioxidants Dissolve vitamin C powder (0.75%) in 5% water and add it to the mixed solution, stirring evenly.

[0026] (5) Supplement water Add the remaining water to adjust to the target formula total (100%), continue stirring for 10 minutes, and then sterilize using a 0.22 μm filter to obtain the hypoglycemic drug.

[0027] Example 4: This example prepares a composition and medicine with hypoglycemic function The composition consists of 5% burdock root extract, 1% ivy extract, 0.3% hypoglycemic decapeptide (amino acid sequence: LRSELAAWSR), 3% trehalose, 0.5% sodium benzoate, 0.5% glycerol, 0.5% vitamin C, and water to make up to 100% of the total volume.

[0028] The preparation method for the hypoglycemic drug is the same as in Example 3.

[0029] Example 5: This example describes the preparation of a composition and drug with hypoglycemic function. The composition consists of 4% burdock root extract, 2% ivy extract, 0.2% hypoglycemic decapeptide (amino acid sequence: LRSELAAWSR), 2% trehalose, 0.25% sodium benzoate, 1% glycerol, 1% vitamin C, and water to make up to 100% of the total.

[0030] The preparation method of the hypoglycemic drug is the same as that in Example 3.

[0031] Comparative Example 1: The composition of this composition is 3% burdock root extract, 2% sage extract, 2% trehalose, 0.2% sodium benzoate, 1% glycerin, 0.75% vitamin C, and water to make up to 100% of the total amount.

[0032] The preparation method of the hypoglycemic drug is the same as that in Example 3.

[0033] Comparative Example 2: The composition of this composition is 2% Ilex chinensis extract, 0.1% hypoglycemic decapeptide (amino acid sequence: LRSELAAWSR), 2% trehalose, 0.2% sodium benzoate, 1% glycerol, 0.75% vitamin C, and water to make up to 100% of the total.

[0034] The preparation method of the hypoglycemic drug is the same as that in Example 3.

[0035] Comparative Example 3: The composition of this composition is 3% burdock root extract, 0.1% hypoglycemic decapeptide (amino acid sequence: LRSELAAWSR), 2% trehalose, 0.2% sodium benzoate, 1% glycerol, 0.75% vitamin C, and water to make up to 100% of the total.

[0036] Comparative Example 4: The composition of this composition is 3% burdock root decoction extract, 2% ivy decoction extract, 0.1% hypoglycemic decapeptide (amino acid sequence: LRSELAAWSR), 2% trehalose, 0.2% sodium benzoate, 1% glycerol, 0.75% vitamin C, and water to make up to 100% of the total.

[0037] The burdock root decoction extract and the evergreen holly decoction extract are extracts obtained by mixing burdock root or evergreen holly powder with water in a mass volume ratio of 1:10, and then decocting at 90° C. for 2 hours.

[0038] Comparative Example 5: The composition of this composition is 3% burdock root extract, 2% ivy extract, 0.1% hypoglycemic decapeptide (amino acid sequence: LRSELAAWSR), 2% trehalose, 0.2% sodium benzoate, 1% glycerol, 0.75% vitamin C, and water to make up to 100% of the total.

[0039] The single extract of burdock root was obtained by direct extraction using 70% ethanol, 40°C, and 250w ultrasonic extraction for 60 minutes; The single extract of Sijiqing was obtained by directly using 70% ethanol, 40°C, and 250w ultrasonic extraction for 60 minutes.

[0040] Comparative Example 6: The composition of this composition is 3% kudzu root extract, 2% black goji berry extract, 0.1% hypoglycemic decapeptide (amino acid sequence: LRSELAAWSR), 2% trehalose, 0.2% sodium benzoate, 1% glycerol, 0.75% vitamin C, and water to make up to 100% of the total.

[0041] The kudzu root extract is obtained by soaking kudzu root tuber powder in 70% ethanol solution at a ratio of 1:10 and extracting at room temperature for 24 hours. The black wolfberry extract is obtained by soaking black wolfberry fruit powder in 50% ethanol at a ratio of 1:10, and extracting it at 40°C and 250w ultrasonic wave for 60 minutes.

[0042] Example 6: Detection of the effects of feeding different compositions on diabetic mice Construction of type 2 diabetes mouse model SPF-grade C57BL / 6J mice in good health were selected and adaptively raised for one week. The environment was controlled as follows: temperature: 22±2℃, relative humidity: 50%-60%, and light cycle: 12 hours light / 12 hours dark.

[0043] Six mice were randomly selected as the blank control group and fed with standard feed, and the remaining mice were fed with a high-sugar and high-fat feed containing 10.0% lard, 20.0% sucrose, 2.5% cholesterol, 1.0% bile salt and 66.5% standard feed.

[0044] After 3 weeks of continuous feeding, the mice were fasted for 12 hours and allowed to drink water freely.

[0045] The blank control group was given citrate buffer (pH=4.4) at a dose of 100 mg / kg via intraperitoneal injection; The model group was given STZ solution (100 mg / kg, dissolved in citrate buffer) by intraperitoneal injection.

[0046] After 3 consecutive days of injection, the type 2 diabetes model mice were established.

[0047] 72 hours after modeling, the tails were cut and blood was collected to test blood glucose. Mice with blood glucose levels exceeding 11.0 mmol / L were considered to have successfully modeled and were used for subsequent experiments.

[0048] Drug administration and fasting blood glucose testing Six mice fed with a standard diet were selected as a blank control group, and the mice were gavaged with 0.1 mL (average weight of about 20 g) of pure water daily. Mice with successful modeling were selected as an experimental group. The experimental group was divided into 10 groups (type 2 diabetes model group and treatment groups 1-9), with 6 mice in each group. The mice in the type 2 diabetes model group were gavaged with 0.1 mL of pure water daily, and the mice in the treatment groups 1-9 were gavaged with different hypoglycemic drugs prepared in Examples 3-5 and Comparative Examples 1-6 daily.

[0049] After 3 weeks of continuous administration, all mice were fasted for 12 h to prevent food intake from affecting blood glucose levels.

[0050] Blood was collected by tail clipping to detect fasting blood glucose concentration in mice after different experimental treatments.

[0051] Table 1. Differences in fasting blood glucose concentration in mice

[0052] pass Figure 1 The results in Table 1 indicate that the blood glucose concentration of mice in the blank control group was 6.20 ± 0.22 mmol / L, indicating that the blood glucose level of normal mice was stable and within the normal physiological range. In contrast, the fasting blood glucose concentration of mice in the type 2 diabetes model group was 19.46 ± 1.36 mmol / L, significantly higher than that in the blank control group, confirming that the diabetes model was successfully established.

[0053] In the treatment groups, the blood glucose concentrations of mice in treatment groups 1, 2, and 3 were 8.30±0.63 mmol / L, 9.32±0.67 mmol / L, and 9.81±0.72 mmol / L, respectively, which were significantly lower than those in the model group and close to normal levels. Treatment group 1 showed the most significant blood glucose reduction effect and was statistically different from treatment groups 2 and 3, indicating that the hypoglycemic drug prepared in Example 3 had the best hypoglycemic effect. This may be attributed to the rational coordination of the proportions of the drug components and the complementary multi-target mechanism of action. For example, burdock root extract works by improving insulin sensitivity, the appropriate proportion of *Ilex chinensis* extract enhances the antioxidant effect, and the hypoglycemic decapeptide inhibits the activity of α-amylase and α-glucosidase. Through the synergistic therapeutic effect of multiple targets, the ideal hypoglycemic effect was ultimately achieved.

[0054] In contrast, while blood glucose levels decreased in Treatment Groups 4, 5, and 6, the effect was limited. This suggests that when key ingredients (burdock root extract, evergreen extract, or hypoglycemic decapeptide) are missing, the synergistic effect of the hypoglycemic drugs is compromised, preventing a significant reduction in blood glucose levels. In particular, when the active ingredient is missing, the overall efficacy of the drug is far from optimal.

[0055] Furthermore, the results of treatment groups 7 and 8 showed that the burdock root extract and *Ilex chinensis* extract obtained by decoction extraction or single extraction without ethanol concentration and temperature adjustment, while slightly better than the groups lacking core components, still failed to produce a synergistic effect with the hypoglycemic peptides. This may be because the decoction extraction method, under high-temperature conditions, may cause the degradation of some heat-sensitive active ingredients (such as polyphenols and flavonoids), resulting in insufficient activity of the extract. The single extraction method, on the other hand, does not completely extract complex components from the plant, also leading to a lack of synergistic hypoglycemic effect.

[0056] Finally, the results of treatment group 9 showed that although kudzu root extract and black goji berry extract also have certain hypoglycemic effects, when used in combination with hypoglycemic peptides, they failed to produce the significant synergistic effect seen in burdock root extract and holly extract. This indicates that when hypoglycemic peptides work together with the burdock root extract and holly extract prepared in this invention, they can form an effective synergistic effect, and none of them can be omitted, further demonstrating the important role of these components in the treatment of diabetes.

[0057] Example 7: The blood obtained from different experimental treatments in Example 6 was placed in centrifuge tubes, and the centrifuge speed was set to 3500 rpm and the time was set to 15 minutes for centrifugation; After centrifugation, the supernatant serum was collected, and the total cholesterol content in mouse serum was detected by radioimmunoassay. The results are shown in Table 2 and... Figure 2 shown.

[0058] Table 2. Differences in total cholesterol content in mice

[0059] From Table 2 and Figure 2 The results showed that the total cholesterol of mice in the diabetic model group was significantly increased, reflecting the metabolic disorder and abnormal lipid metabolism caused by diabetes.

[0060] In treatment groups 1-3, especially treatment group 1, a better cholesterol-lowering effect was observed, with a significant reduction in total cholesterol levels. This indicates that the hypoglycemic drugs prepared in Examples 3-5 can effectively improve total cholesterol metabolism abnormalities caused by diabetes. Furthermore, the effect of treatment group 1 was superior to that of treatment groups 2 and 3, similar to the results of blood glucose testing, further validating the advantages of the hypoglycemic drug prepared in Example 3, whose effect was significantly better than that of the drugs prepared in Examples 4 and 5. This demonstrates that the optimal synergistic effect was achieved at this combination ratio. The results of treatment groups 4 to 6 showed that in the absence of the core active ingredient, the drug's effect on restoring abnormal total cholesterol metabolism was relatively limited, indicating that when the key ingredient is missing, the synergistic effect of the drug cannot be fully exerted and the cholesterol-lowering effect is also affected.

[0061] The results from treatment groups 7 and 8 further demonstrated that burdock root extracts and burdock root extracts obtained using either the decoction or single extraction methods were unable to significantly restore abnormal cholesterol metabolism in diabetic mice. This may be because the decoction and single extraction methods may result in insufficient activity of the extracted components, thus affecting the overall efficacy of the drugs.

[0062] Finally, the results of treatment group 9 were consistent with the results of blood glucose testing. Although the drug prepared by replacing burdock root extract and evergreen extract showed a certain cholesterol-lowering effect, it could not produce a synergistic effect with hypoglycemic peptides, indicating that in the cholesterol metabolism abnormalities caused by diabetes treatment, the combination of burdock root extract, evergreen extract and hypoglycemic peptides is indispensable.

[0063] Example 8: Detecting the effect of the hypoglycemic drugs prepared in Examples 3-5 of the present invention on oxidative damage and inflammatory response caused by diabetes The blood of the blank control group, type 2 diabetes model group, treatment group 1, treatment group 2, and treatment group 3 obtained in Example 6 was placed in a centrifuge tube, and the centrifuge speed was set to 3500 rpm and the time was set to 15 minutes for centrifugation; After centrifugation, the upper serum was collected and the levels of SOD and IL-6 in the serum were detected using superoxide dismutase (SOD) ELISA kit and tumor necrosis factor-α (TNF-α) ELISA kit. The results are shown in Table 3 and Figure 3 and Figure 4 shown.

[0064] Table 3 Differences in SOD and TNF-α levels in mice

[0065] As shown in Table 3, the SOD (superoxide dismutase) level in the blank control group was 193.07±11.68 U / ml, indicating that the antioxidant enzyme activity in healthy mice was at normal levels, effectively scavenging free radicals and maintaining redox balance in the body. However, in the type 2 diabetes model group, the SOD level dropped significantly to 99.26±4.96 U / ml, indicating that the diabetic mice experienced a significant increase in oxidative stress and a significant decrease in antioxidant capacity. This may be related to the hyperglycemic state caused by diabetes, leading to the accumulation of free radicals and increased oxidative damage.

[0066] Under the intervention of the hypoglycemic drugs prepared in Examples 3-5, SOD activity was restored. Specifically, the SOD content in treatment group 1 was 174.28±9.86 U / ml, in treatment group 2 it was 139.05±9.91 U / ml, and in treatment group 3 it was 144.91±8.66 U / ml. Although the degree of SOD recovery varied among the groups, all demonstrated the positive effects of hypoglycemic drugs in improving the antioxidant capacity of diabetic mice, indicating that these drugs can effectively alleviate the oxidative damage caused by diabetes.

[0067] In terms of TNF-α (tumor necrosis factor-α) levels, the blank control group had a normal physiological level of 23.90±2.78 pg / mL. However, in the type 2 diabetes model group, TNF-α levels significantly increased to 72.29±3.35 pg / mL, indicating a significant inflammatory response in diabetic mice. A hyperglycemic environment typically promotes a chronic, low-grade inflammatory response, further exacerbating the pathological process of diabetes.

[0068] After treatment with glucose-lowering drugs, TNF-α levels in treatment groups 1, 2, and 3 dropped to 31.04±3.99 pg / mL, 44.95±2.88 pg / mL, and 40.74±3.09 pg / mL, respectively, demonstrating that these drugs effectively inhibited the inflammatory response in diabetic mice. In particular, treatment group 1 showed the greatest decrease in TNF-α levels, indicating that this group of drugs is significantly effective in alleviating diabetes-induced inflammation.

[0069] In treatment groups 1, 2, and 3, TNF-α levels decreased to 31.04±3.99 pg / mL, 44.95±2.88 pg / mL, and 40.74±3.09 pg / mL, respectively. This indicates that the hypoglycemic agents of Examples 3-5 can effectively inhibit the inflammatory response in diabetic mice. Further comparison of the drug effects of Example 3, Example 4, and Example 5 shows that the hypoglycemic drug prepared in Example 3 exhibits the best effect in improving SOD activity and inhibiting TNF-α levels. In contrast, although the drugs of Example 4 and Example 5 also have certain improvement effects, the effects are not as significant as those of Example 3. This shows that the drug prepared in Example 3 has a stronger synergistic effect in reducing oxidative damage and inflammatory reactions caused by diabetes, and the optimization and ratio of the drug ingredients bring about better therapeutic effects. Therefore, the hypoglycemic drug prepared in Example 3 shows more outstanding clinical potential in the antioxidant and anti-inflammatory treatment of diabetes.

Claims

1. A composition having a blood sugar lowering function, characterized in that: The composition is composed of the following ingredients by mass percentage: 3%-5% burdock root extract, 1%-2% evergreen extract, 0.1%-0.3% hypoglycemic decapeptide, 2%-3% trehalose, 0.2%-0.5% sodium benzoate, 0.5%-1% glycerol, 0.5%-0.75% vitamin C, and water supplemented to 100%; The amino acid sequence of the hypoglycemic decapeptide is LRSELAAWSR.

2. The composition according to claim 1, characterized in that The preparation method of the burdock root extract comprises the following steps: (1) removing impurities from dried burdock roots, washing them clean, slicing them and crushing them into burdock root powder; (2) Mix burdock root powder with 50% ethanol in a mass-to-volume ratio of 1:10 and extract with ultrasonic wave for 30 min at 50°C and 250W. (3) Filtering with a filter to collect the extract a and the filter residue; (4) The filter residue was mixed with 70% ethanol at a mass-to-volume ratio of 1:10, and ultrasonic extraction was performed for 30 min at a temperature of 50°C and a power of 250W; (5) filtering with a filter to collect extract b, combining extract a and extract b to obtain a mixed extract; (6) Concentrating the mixed extract to 1 / 10 of the original volume to obtain a concentrated extract; (7) freeze-drying the concentrated extract to obtain a burdock root extract; The preparation method of the Sijiqing extract comprises the following steps: (1) Remove impurities from the dried Evergreen leaves, clean them, and grind them into Evergreen powder; (2) Add 50% ethanol solution to the Sijiqing powder at a mass volume ratio of 1:10 and extract at room temperature for 24 hours; (3) Filtering with a filter to collect the extract a and the filter residue; (4) Mix the filter residue with 70% ethanol in a mass-to-volume ratio of 1:8 and extract by ultrasonic at 40°C and 250W for 30 minutes; (5) filtering with a filter to collect extract b, combining extract a and extract b to obtain a mixed extract; (6) Concentrating the mixed extract to 1 / 10 of the original volume using a rotary evaporator to obtain a concentrated extract; (7) The concentrated extract is freeze-dried to obtain an ivy leaf extract.

3. The composition according to claim 2, characterized in that The composition consists of the following ingredients in percentage by mass: 3% burdock root extract, 2% ivy extract, 0.1% hypoglycemic decapeptide, 2% trehalose, 0.2% sodium benzoate, 1% glycerol, 0.75% vitamin C, and water supplemented to 100%.

4. The composition according to claim 3, characterized in that The composition is used for reducing elevated blood sugar caused by type 2 diabetes.

5. Use of a composition in the preparation of a drug for treating type 2 diabetes, characterized in that: The composition is composed of the following ingredients by mass percentage: 3%-5% burdock root extract, 1%-2% evergreen extract, 0.1%-0.3% hypoglycemic decapeptide, 2%-3% trehalose, 0.2%-0.5% sodium benzoate, 0.5%-1% glycerol, 0.5%-0.75% vitamin C, and water supplemented to 100%; The amino acid sequence of the hypoglycemic decapeptide is LRSELAAWSR; The burdock root extract is prepared according to the preparation method of the burdock root extract according to claim 2; The ivy extract is prepared according to the preparation method of the ivy extract described in claim 2.

6. The use according to claim 5, characterized in that: The drug for treating type 2 diabetes is used to reduce elevated blood sugar caused by diabetes and improve abnormal cholesterol metabolism, oxidative damage and inflammatory response caused by diabetes.

7. The use according to claim 6, characterized in that: The composition consists of the following ingredients in percentage by mass: 3% burdock root extract, 2% ivy extract, 0.1% hypoglycemic decapeptide, 2% trehalose, 0.2% sodium benzoate, 1% glycerol, 0.75% vitamin C, and water supplemented to 100%.

Images